Step 1 of 4 · Understand phase

Understand

Master the fundamentals of Joint Clinical Assessment (JCA) in the EU healthcare system. JCA-AI provides comprehensive guidance on EU HTA Regulation 2021/2282, the role of EUnetHTA 21, and how JCA fits into the broader European health technology assessment landscape.

Learn about JCA scope—which health technologies require JCA, timelines for implementation, and how JCA relates to national HTA processes. Understand the roles of different stakeholders: Member States, EUnetHTA 21 Coordination Group, assessment teams, and pharmaceutical companies.

Get clarity on JCA objectives: creating a single, EU-wide clinical assessment to reduce duplication, improve efficiency, and support evidence-based decision-making across Member States.

Understand capabilities

  • EU HTA Regulation 2021/2282: objectives, scope, and implementation timeline
  • EUnetHTA 21 structure: Coordination Group, assessment teams, and secretariat
  • JCA vs. national HTA: what's centralized vs. what remains national
  • Which technologies require JCA: new medicines, advanced therapies, orphan drugs
Example: "What is JCA?" → Joint Clinical Assessment is a centralized EU process evaluating the clinical effectiveness and safety of new health technologies, creating a single assessment used by all Member States.
Step 2 of 4 · Prepare phase

Prepare

Build a robust JCA submission with comprehensive documentation and evidence. JCA-AI guides you through the PICOS framework (Population, Intervention, Comparator, Outcomes, Study design), helping you define research questions and structure your clinical evidence.

Understand JCA dossier requirements—from clinical study reports and systematic literature reviews to patient input and real-world evidence. Learn how to prepare protocol submissions, scoping meetings, and clarification responses.

Access templates, checklists, and best practices for organizing clinical data, addressing evidence gaps, and presenting information in formats that meet EUnetHTA 21 standards and expectations.

Prepare details

  • Population: Define target patient population, subgroups, disease characteristics
  • Intervention: Specify the health technology, dosing, administration, duration
  • Comparator: Identify relevant comparators (standard of care, placebo, active controls)
  • Outcomes: List clinical endpoints (efficacy, safety, patient-reported outcomes)
  • Study design: Describe study types, methodologies, and evidence quality
Example: For a new oncology drug, PICOS defines: adults with metastatic melanoma (P), drug X 200mg daily (I), vs. pembrolizumab (C), measuring OS, PFS, AEs (O), from RCTs and observational studies (S).
Step 3 of 4 · Assess phase

Assess

Navigate the JCA assessment process with confidence. JCA-AI explains how assessment teams evaluate clinical effectiveness, safety, and quality of evidence using standardized methodologies and GRADE (Grading of Recommendations Assessment, Development and Evaluation) frameworks.

Understand assessment domains: relative effectiveness (vs. comparators), absolute effectiveness (clinical benefit), safety profile (adverse events, long-term risks), and uncertainty analysis (evidence quality, generalizability, subgroup considerations).

Learn how assessors critically appraise evidence, synthesize findings, and produce JCA reports that inform national HTA decisions. Prepare for potential challenges, address evidence limitations, and position your technology for favorable assessment outcomes.

Assess details

  • Relative effectiveness: Comparative benefit vs. standard of care or active comparators
  • Absolute effectiveness: Clinical benefit in target population (response rates, survival)
  • Safety: Adverse event profile, serious AEs, treatment discontinuations, long-term risks
  • Uncertainty: Evidence quality (GRADE), generalizability, subgroup effects, evidence gaps
Example: Assessment evaluates if new drug shows statistically significant OS improvement vs. comparator (relative effectiveness), absolute OS gain (e.g., 3 months), safety profile (grade 3/4 AEs), and evidence certainty (high/moderate/low).
Step 4 of 4 · Collaborate phase

Collaborate

Engage effectively with JCA stakeholders throughout the assessment process. JCA-AI provides guidance on stakeholder consultation opportunities, patient and clinical expert involvement, and how to respond to assessment team questions and feedback.

Understand how JCA reports are used by Member States for national HTA decisions. Learn about the transition from JCA to national processes—what's binding, what's advisory, and how to support national agencies with additional evidence or economic evaluations.

Master post-JCA activities: monitoring real-world outcomes, updating evidence as new data emerges, and preparing for reassessments or indication expansions. Build collaborative relationships with assessors, payers, and patient organizations to support successful market access across the EU.

Collaborate details

  • Patient organization involvement: input on outcomes, quality of life, unmet needs
  • Clinical expert consultation: treatment landscape, clinical practice, guideline alignment
  • Scoping meeting participation: discussing protocol, research questions, methods
  • Clarification process: responding to assessment team questions, providing additional data
Example: During scoping, patient organizations highlight treatment burden and quality of life as critical outcomes, influencing which endpoints assessors prioritize in the JCA.